Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms

Exclusion Criteria

• •Known central nervous system (CNS) involvement by lymphoma
• •Previously received immune checkpoint therapy
• •Prior malignancy within the past 3 years, except for curatively treated basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or localized Gleason score 6 or lower prostate cancer
• •Active autoimmune disease or history of autoimmune diseases that may relapse with some exceptions
• •Severe or debilitating pulmonary disease
• •Clinically significant cardiovascular disease
• •Active fungal, bacterial, and/or viral infection requiring systemic therapy
• •Known infection with HIV or active viral hepatitis B or C infection
• •Major surgery within 4 weeks of the first dose of study drug
• •Pregnant or lactating women
• •Vaccination with a live vaccine within 35 days prior to the first dose of study drug
• •Hypersensitivity to tislelizumab
• •Concurrent participation in another therapeutic clinical trial